Endofotonics raises S$12m in Series B funding, led by Singapore Medical Group
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
CANCER diagnostic company Endofotonics on Friday said it has raised S$12 million in a Series B round led by executives from locally listed healthcare company Singapore Medical Group.
The additional funding will be used to drive commercialisation of its early gastric cancer detection system in the Asia-Pacific, and to expand the coverage of its cancer detection technology to other organs.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025
